Vitekta

Vitekta Uses, Dosage, Side Effects, Food Interaction and all others data.

Vitekta is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection. Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.

Vitekta was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. On September 24, 2014, the FDA approved the single pill form of elvitegravir.

Trade Name Vitekta
Availability Prescription only
Generic Elvitegravir
Elvitegravir Other Names elvitégravir, Elvitegravir, GS 9137
Related Drugs Biktarvy, Truvada, tenofovir, ritonavir, Complera, Atripla, Stribild
Type
Formula C23H23ClFNO5
Weight Average: 447.884
Monoisotopic: 447.124878763
Protein binding

Elvitegravir is 98–99% bound to human plasma proteins

Groups Approved
Therapeutic Class
Manufacturer
Available Country Canada, United States
Last Updated: September 19, 2023 at 7:00 am
Vitekta
Vitekta

Uses

Vitekta is an antiretroviral agent used in combination with other antiretrovirals for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.

Vitekta in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.

Vitekta is also used to associated treatment for these conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

How Vitekta works

Vitekta is an HIV-1 integrase strand transfer inhibitor (INSTI). Integrase is an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. Vitekta does not inhibit human topoisomerases I or II.

Toxicity

The most common adverse reactions reported for elvitegravir use during clinical trials include nausea, vomiting, and diarrhea. Less common side effects occurring in <2% of patients, include abdominal pain, dyspepsia, fatigue, insomnia, rash, depression, suicidal ideation, and suicidal attempt.

Food Interaction

  • Avoid St. John's Wort. This herb induces the CYP3A metabolism of elvitegravir. Therefore, it may reduce the serum concentration of elvitegravir and its effectiveness.
  • Take separate from antacids. Take at least 2 hours before or after antacids.
  • Take with food.

[Moderate] ADJUST DOSING INTERVAL: Food enhances the oral bioavailabilities of both elvitegravir and tenofovir.

When a single dose of cobicistat

When administered with a high-fat meal (approximately 800 kcal; 50% fat), the mean AUC of elvitegravir and tenofovir increased by 87% and 23%, respectively, relative to fasting conditions.

The alterations in mean AUCs of cobicistat and emtricitabine were not clinically significant with either the light or high-fat meal.

MANAGEMENT: Cobicistat

Vitekta as a single-ingredient preparation should also be administered once daily with food.

Vitekta Disease Interaction

Major: hepatic dysfunction, renal dysfunction

Elimination Route

Following oral administration of elvitegravir and ritonavir with food, in HIV-1 infected subjects, peak elvitegravir plasma concentrations were observed approximately 4 hours post-dose.

Half Life

The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.

Elimination Route

Following oral administration of [14C]elvitegravir/ritonavir, 94.8% of the dose was recovered in feces, while 6.7% was recovered in urine as metabolites.

Innovators Monograph

You find simplified version here Vitekta

*** Taking medicines without doctor's advice can cause long-term problems.
Share